CHORAGON (u-hCG) is a glycopeptide hormone administered by intramuscular injection and used to control the timing of ovulation.
HCG mimics the action of LH and is the drug of choice to trigger ovulation following follicular stimulation and development. It is also used in combination with MENOPUR / MENOGON to stimulate spermatogenesis in male infertility due to hypogonadism.
DURATOCIN (carbetocin) is Ferring's long-acting, oxytocin analogue that is used to prevent haemorrhage following caesarean section.
Haemorrhaging from the uterus can occur following an incomplete abortion, a caesarean section or following the final stage of labour, once the placenta has been expelled, due to insufficient tone in the uterus (atony).
DURATOCIN is administered via a single intravenous injection before or after the delivery of the placenta.
MENOPUR has indications for treatment of female and male infertility in the following groups of patients:
Anovulatory women: MENOPUR can be used to stimulate follicle development in amenorrhoeic patients Women undergoing superovulation within a medically assisted fertilisation programme: MENOPUR can be used to induce multiple follicular development in patients undergoing an assisted conception technique such as in-vitro fertilisation (IVF).
Hypogonadotrophic hypogonadism in men: MENOPUR may be given in combination with human chorionic gonadotrophin (e.g. CHORAGON®) for the stimulation of spermatogenesis.
With this: Highly purified menotrophin (MENOPURTM) is indicated for the treatment of infertility in the following clinical situations: Anovulation, including polycystic ovarian disease (PCOD) in women who have been unresponsive to treatment with clomiphene citrate. Controlled ovarian hyperstimulation to induce the development of multiple follicles for assisted reproductive technologies (ART) (e.g. in vitro fertilisation/embryo transfer (IV/ET). Gamete intra-fallopian transfer (GIFT) and intracytoplasmic sperm injection (ICSI). Stimulation of follicular development in women with hypogonadotrophic hypogonadism.
PROPESS® (dinoprostone) is indicated for initiation of cervical ripening in patients at term.
PROPESS is administered through a vaginal insert contained in a polyester pouch with a withdrawal tape. PROPESS releases dinoprostone at a constant and controlled rate. If, for any reason, treatment must be interrupted, the vaginal insert can quickly and easily be pulled out.
TRACTOCILE (atosiban) is a treatment indicated to delay imminent pre-term birth, which is the main cause of death and disability in new-born infants. The active ingredient, atosiban, is an oxytocin/vasopressin antagonist that blocks the action of oxytocin and is able to prevent uterine contractions and relax the uterus.
TRACTOCILE is administered by an intravenous infusion in three successive stages to delay imminent pre-term birth.
ENDOMETRIN (progesterone) is an effervescent vaginal tablet containing 100 mg progesterone per tablet. It is indicated for luteal support as part of an Assisted Reproductive Technology (ART) treatment program for infertile women.